



NOTICES

DEPARTMENT OF HEALTH

Approval of Drugs Which May be Used by Certain Optometrists

[48 Pa.B. 2348]

[Saturday, April 21, 2018]

Under the Optometric Practice and Licensure Act (63 P.S. §§ 244.1—244.12), as amended by the act of December 16, 2002 (P.L. 1950, No. 225) (Act 225), the Secretary of Health (Secretary) has the authority to approve drugs for use in the "practice of optometry" as defined in Act 225. The Chairperson of the State Board of Optometry (Board) sent the Secretary a letter on February 8, 2018, and requested that the Secretary approve the use of the following drug. Act 225 requires the Secretary, within 90 days of the receipt of a request from the Board, to approve or disapprove for good cause each drug submitted. The Secretary has found good cause to approve the use of the following drug in the practice of optometry:

Netarsudil ophthalmic solution (Rhopressa®) 0.02%

The approval of the use of this drug is effective upon publication of this notice in the *Pennsylvania Bulletin*.

Persons with a disability who require an alternative format of this notice (for example, large print, audiotope, Braille) should contact Susan Coble, Director, Bureau of Community Program Licensure and Certification, 132 Kline Plaza, Suite A, Harrisburg, PA 17104, (717) 783-8665, or for speech and/or hearing-impaired persons, call the Pennsylvania AT&T Relay Service at (800) 654-5984 (TDD users) or (800) 654-5988 (voice users).

RACHEL L. LEVINE, MD,
Secretary

[Pa.B. Doc. No. 18-610. Filed for public inspection April 20, 2018, 9:00 a.m.]

No part of the information on this site may be reproduced for profit or sold for profit.

This material has been drawn directly from the official *Pennsylvania Bulletin* full text database. Due to the limitations of HTML or differences in display capabilities of different browsers, this version may differ slightly from the official printed version.



webmaster@PaBulletin.com